Jessie Denise Coty, NP
Nurse Practitioner · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jessie Denise Coty’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence C22118 · Cancelled
Licence status: Cancelled · since 1960 · University of Pennsylvania School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$209,295
Pharmacies billed $209,295 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
23 generic and fewer than 11 brand-name prescriptions · $209,295 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 40 | 19 | None | None | $209,295 |
| 2023 | 483 | 95 | 3% (15) | 16% | $746,042 |
| 2022 | 531 | 102 | 6% (29) | None | $807,502 |
| 2021 | 237 | 57 | None | 34% | $740,316 |
| 2020 | 323 | 59 | 7% (24) | 43% | $875,002 |
| 2019 | 414 | 72 | 15% (62) | 26% | $254,796 |
| 2018 | 348 | 75 | 23% (80) | 22% | $597,992 |
| 2017 | 325 | 60 | 25% (81) | 23% | $166,567 |
| 2016 | 374 | 62 | 20% (75) | None | $156,764 |
| 2015 | 335 | 65 | 19% (62) | 17% | $79,428 |
| 2014 | 281 | 70 | 19% (52) | None | $50,993 |
| 2013 | 117 | 23 | None | 19% | $47,962 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Mekinist | 16 | $230,881 | $14,430 |
| Tafinlar | 18 | $223,542 | $12,419 |
| Ondansetron | 64 | $1,272 | $20 |
| Gabapentin | 17 | $908 | $53 |
| Levothyroxine | 62 | $641 | $10 |
| Prochlorperazine Maleate | 46 | $568 | $12 |
| Bicalutamide | 23 | $484 | $21 |
| Dexamethasone | 42 | $413 | $10 |
| Lorazepam | 27 | $134 | $5 |
| Zolpidem | 12 | $38 | $3 |
2022: 15 drugs
| Lenvima | 16 | $337,018 | $21,064 |
| Mekinist | 11 | $125,144 | $11,377 |
| Tafinlar | 13 | $121,933 | $9,379 |
| Baraclude | 12 | $12,336 | $1,028 |
| Ondansetron | 58 | $1,271 | $22 |
| Levothyroxine | 73 | $739 | $10 |
| Oxycodone | 17 | $571 | $34 |
| Prochlorperazine Maleate | 47 | $562 | $12 |
| Ondansetron Odt | 18 | $494 | $27 |
| Bicalutamide | 17 | $389 | $23 |
| Dexamethasone | 17 | $242 | $14 |
| Lorazepam | 34 | $166 | $5 |
| Lisinopril | 15 | $65 | $4 |
| Metoclopramide | 12 | $60 | $5 |
| Prednisone | 13 | $49 | $4 |
2021: 5 drugs
| Lenvima | 24 | $478,692 | $19,945 |
| Mekinist | 15 | $137,336 | $9,156 |
| Tafinlar | 16 | $118,067 | $7,379 |
| Levothyroxine | 44 | $474 | $11 |
| Ondansetron | 25 | $425 | $17 |
2020: 8 drugs
| Lenvima | 18 | $347,232 | $19,291 |
| Mekinist | 24 | $263,876 | $10,995 |
| Tafinlar | 26 | $229,891 | $8,842 |
| Levothyroxine | 74 | $1,019 | $14 |
| Gabapentin | 11 | $534 | $49 |
| Ondansetron | 13 | $213 | $16 |
| Lidocaine Hcl Viscous | 13 | $172 | $13 |
| Prochlorperazine Maleate | 11 | $116 | $11 |
2019: 9 drugs
| Levothyroxine | 75 | $1,094 | $15 |
| Oxycodone | 28 | $901 | $32 |
| Gabapentin | 18 | $703 | $39 |
| Ondansetron | 32 | $517 | $16 |
| Prochlorperazine Maleate | 26 | $321 | $12 |
| Dexamethasone | 17 | $259 | $15 |
| Prednisone | 18 | $100 | $6 |
| Lorazepam | 15 | $83 | $6 |
| Metoclopramide | 13 | $55 | $4 |
2018: 7 drugs
| Lenvima | 31 | $544,273 | $17,557 |
| Oxycodone | 32 | $1,364 | $43 |
| Fentanyl | 13 | $1,158 | $89 |
| Levothyroxine | 34 | $554 | $16 |
| Ondansetron | 27 | $428 | $16 |
| Hydrocodone-Acetaminophen | 12 | $239 | $20 |
| Prochlorperazine Maleate | 16 | $129 | $8 |
2017: 10 drugs
| Hydrocodone-Acetaminophen | 16 | $1,404 | $88 |
| Morphine Sulfate | 20 | $1,331 | $67 |
| Fentanyl | 13 | $982 | $76 |
| Gabapentin | 12 | $840 | $70 |
| Oxycodone | 21 | $721 | $34 |
| Levothyroxine | 31 | $472 | $15 |
| Ondansetron | 12 | $334 | $28 |
| Tamsulosin | 12 | $328 | $27 |
| Omeprazole | 18 | $109 | $6 |
| Lidocaine Hcl Viscous | 11 | $81 | $7 |
2016: 9 drugs
| Clindamycin Phosphate | 11 | $1,297 | $118 |
| Morphine Sulfate | 19 | $1,277 | $67 |
| Fentanyl | 19 | $1,139 | $60 |
| Gabapentin | 14 | $960 | $69 |
| Hydrocodone-Acetaminophen | 22 | $934 | $42 |
| Levothyroxine | 69 | $707 | $10 |
| Pantoprazole | 12 | $140 | $12 |
| Lorazepam | 12 | $87 | $7 |
| Lidocaine Hcl Viscous | 13 | $48 | $4 |
2015: 11 drugs
| Fentanyl | 19 | $1,949 | $103 |
| Gabapentin | 12 | $1,335 | $111 |
| Ondansetron | 13 | $1,173 | $90 |
| Oxycodone | 14 | $986 | $70 |
| Morphine Sulfate | 11 | $606 | $55 |
| Levothyroxine | 18 | $305 | $17 |
| Dexamethasone | 13 | $140 | $11 |
| Lorazepam | 22 | $123 | $6 |
| Prochlorperazine Maleate | 15 | $110 | $7 |
| Metoclopramide | 11 | $49 | $4 |
| Famotidine | 11 | $37 | $3 |
2014: 8 drugs
| Clindamycin Phosphate | 12 | $1,829 | $152 |
| Fentanyl | 13 | $960 | $74 |
| Hydrocodone-Acetaminophen | 18 | $396 | $22 |
| Levothyroxine | 19 | $236 | $12 |
| Ondansetron | 14 | $205 | $15 |
| Prochlorperazine Maleate | 13 | $90 | $7 |
| Lorazepam | 18 | $83 | $5 |
| Dexamethasone | 12 | $56 | $5 |
2013: 2 drugs
| Levothyroxine | 27 | $224 | $8 |
| Lorazepam | 14 | $54 | $4 |
Money from drug and device companies
$29 in 2023
| 2023 | 1 | 1 | None | $29 |
| 2021 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $29 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2023-10-24 | Keytruda | $29 |
See earlier years (2021)
2021: $20
| Eisai | Lenvima | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407193386
- Licence
- CA 22118California C22118: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-01-11
- NPI last updated
- 2023-07-07
- NPI record certified
- 2023-07-07
This is when the NPI record was last certified, not a medical board exam.